Vigil Neuroscience’s VG-3927: Promising Phase 1 Results and Strategic Positioning for Phase 2
Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated ...
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral ...
BioSpace4d
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
Nasdaq4d
Vigil Neuroscience Reports Positive Phase 1 Data Supporting Continued Development Of VG-3927
(RTTNews) - Vigil Neuroscience (VIGL) reported positive data from completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimers disease. The company said ...
Vigil Neuroscience shares rise on positive Alzheimer's trial data
Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 ...
Morningstar4d
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and ...
Yahoo Finance4d
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
WATERTOWN, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...
Stockhouse4d
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease
- Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology - WATERTOWN, Mass., Jan. 23, 2025 (GLOBE ...